CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1b Dose-Escalation Study of the AKT Inhibitor MK-2206 (NSC# 749607) Plus Lapatinib (NSC# 727989) Administered in Patients With HER2 Positive Metastatic Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01281163
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:51.188469+00:00
Published At: 2015-08-27T00:00:00+00:00
Record Updated At: 2015-08-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Estrogen Receptor Negative", "Estrogen Receptor Positive", "HER2/Neu Positive", "Progesterone Receptor Negative", "Progesterone Receptor Positive", "Recurrent Breast Carcinoma", "Stage IV Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2015-08-27"
protocolSection.identificationModule.nctId: "NCT01281163"
protocolSection.identificationModule.officialTitle: "A Phase 1b Dose-Escalation Study of the AKT Inhibitor MK-2206 (NSC# 749607) Plus Lapatinib (NSC# 727989) Administered in Patients With HER2 Positive Metastatic Breast Cancer"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.